Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 8/20 | 0.34 |
| ▸ | DRD2 | P14416 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5958031 | 1.00 | GSK3B (0.42) | GSK3BCA2DRD4DRD2KDM4E | |
| SCHEMBL5182897 | 0.85 | GSK3B (0.44) | GSK3BALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL5182890 | 0.85 | GSK3B (0.44) | GSK3BALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL5461219 | 0.81 | ATM (0.48) | GSK3BDRD4DRD2KDM4EALDH1A1 | |
| SCHEMBL5461220 | 0.81 | ATM (0.48) | GSK3BDRD4DRD2KDM4EALDH1A1 | |
| SCHEMBL5957900 | 0.77 | SMN1; SMN2 (0.41) | DRD4KDM4EALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL5957901 | 0.77 | SMN1; SMN2 (0.41) | DRD4KDM4EALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL5463441 | 0.76 | GSK3B (0.44) | GSK3BCA2DRD4DRD2KDM4E | |
| SCHEMBL16202068 | 0.76 | DRD4 (0.49) | GSK3BCA2DRD4DRD2KDM4E | |
| SCHEMBL5463436 | 0.76 | GSK3B (0.44) | GSK3BCA2DRD4DRD2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122065-A1 | Amide compound and method of controlling plant disease with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1577290-A1 | AMIDE COMPOUND AND METHOD OF CONTROLLING PLANT DISEASE WITH THE SAME | Sumitomo Chemical Company, Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122065-A1 | Amide compound and method of controlling plant disease with the same | CBR3, C5, CLN6 | GSK3B 4300/4885CA2 1660/4885DRD4 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.